1.
Capra M, Martin T, Moreau P, Baker R, Pour L, Min C-K, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, Risse M-L, Malinge L, Schwab S, Dimopoulos M. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. haematol [Internet]. 2021Oct.14 [cited 2022Jun.25];107(6):1397-409. Available from: https://haematologica.org/article/view/haematol.2021.279229